Clinical trials: Autoimmune State
- Condition Autoimmune State
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
The main purpose of the study is to check: Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or…
- Conditions
- Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
- Trial name
- PreTreg (NCT06688331)
- Testing
- ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab)
- Where
- 9 sites in Poland
- Volunteers
- 150 people
- Sponsor
- PolTREG S.A.
Diabetes Mellitus, Type 1
Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)
The study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial in subjects with established T1D.
- Trial name
- DAY (NCT03794960)
- Testing
- TOL-3021
- Sponsor
- Tolerion, Inc.
Type 1 Diabetes
Stem Cell Educator Therapy in Type 1 Diabetes
The translational potential to the clinical applications of cord blood stem cells has increased enormously in recent years, mainly because of its unique advantages including no risk to the donor, no ethical issues, low risk of…
- Trial name
- NCT01350219
- Testing
- Stem Cell Educator
- Where
- 4 sites in China, Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Throne Biotechnologies Inc.
Arthritis, Juvenile Rheumatoid
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients.
- Trial name
- NCT00637780
- Testing
- Sulfasalazine
- Where
- 2 sites in United States, Mexico
- Volunteers
- 2 people
- Sponsor
- Pfizer
Type 1 Diabetes
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell…
- Trial name
- NCT00435981
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 8 sites in Sweden
- Volunteers
- 70 people
- Sponsor
- Diamyd Therapeutics AB
Arthritis, Rheumatoid
Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics
To compare rheumatoid arthritis (RA) patient characteristics, adherence, and costs between patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs.
- Trial name
- NCT03964649
- Where
- United States
- Volunteers
- 7,308 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity
Investigator initiated, randomised, placebo-controlled, double-blind, multi-centre primary intervention study to assess whether daily administration of B.
- Trial name
- SINT1A (NCT04769037)
- Testing
- B. infantis
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 1,149 people, healthy volunteers welcome
- Sponsor
- Helmholtz Zentrum München
Autoimmunity, Inflammation
Secukinumab Open Label Roll-over Extension Protocol
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are…
- Trial name
- NCT04638647
- Testing
- Secukinumab s.c. injection
- Where
- 171 sites in United States, Brazil and 18 more
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Autism Spectrum Disorder, Autism
Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
Autism spectrum disorder (ASD) is a neurodevelopmental condition with core deficits in social communication and behavior, often accompanied by gastrointestinal (GI) and metabolic dysfunction.
- Conditions
- Autism Spectrum Disorder, Autism, Autism Spectral Disorder
- Trial name
- GARM-Autism (NCT07546942)
- Testing
- Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Black Tie Medical, Inc.
Type 1 Diabetes
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States
This study is an observational, longitudinal, non-interventional real-world study in the United States. The study is meant to describe the experience of participants with a history of stage 2 type 1 diabetes who have been infused…
- Trial name
- TEPLI-QUEST (NCT07260110)
- Testing
- Teplizumab
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Sanofi
Type 1 Diabetes
Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy
Type 1 diabetes (T1D) is an autoimmune disease that usually occurs in children and reduces their pancreatic islet beta cells and thereby limits insulin production.
- Trial name
- NCT01996228
- Testing
- Stem Cell Educator
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.
- Trial name
- SUNRISE (NCT03895437)
- Testing
- TOL-3021
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- Tolerion, Inc.
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.
- Trial name
- DAWN (NCT03794973)
- Testing
- TOL-3021
- Where
- United States
- Sponsor
- Tolerion, Inc.